Angiotensin 1-7 Is a Negative Modulator of Aldosterone Secretion in Vitro and in Vivo

Hypertension

Volumn 68, Issue 2, 2016, Pages 378-384

  Shefer, Gabi ^a   Marcus, Yonit ^a   Knoll, Esther ^a   Dolkart, Oleg ^b   Foichtwanger, Shulamit ^a   Nevo, Nava ^c   Limor, Rona ^a   Stern, Naftali ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

aldosterone; aldosterone system; angiotensin; angiotensins; fructose; hypertension; renin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN[1-7]; CORTICOTROPIN; MAS1 RECEPTOR; POTASSIUM; RENIN; UNCLASSIFIED DRUG; ANGIOTENSIN I; ANGIOTENSIN I (1-7); ANTIHYPERTENSIVE AGENT; PEPTIDE FRAGMENT;

ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; GLOMERULOSA CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OBESITY; OSMOTIC MINIPUMP; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; SODIUM RESTRICTION; ZONA GLOMERULOSA; ANIMAL; BLOOD; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; HYPERTENSION; METABOLISM; PHYSIOLOGY; PROCEDURES; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECRETION (PROCESS);

ALDOSTERONE; ANGIOTENSIN I; ANIMALS; ANTIHYPERTENSIVE AGENTS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; HYPERTENSION; PEPTIDE FRAGMENTS; RATS; RENIN-ANGIOTENSIN SYSTEM; ZONA GLOMERULOSA;

EID: 84973375268     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.07088     Document Type: Article

References (29)

1. Santos RA. Angiotensin-(1-7). Hypertension. 2014;63:1138-1147. doi: 10.1161/HYPERTENSIONAHA.113.01274.
2. Chappell MC, Pirro NT, Sykes A, Ferrario CM. Metabolism of angiotensin-( 1-7) by angiotensin-converting enzyme. Hypertension. 1998;31(1 pt 2):362-367. doi: 10.1161/01.HYP.31.1.362.
3. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension. 1997;30 (3 pt 2):535-541. doi: 10.1161/01.HYP.30.3.535.
4. Souza ÁP, Sobrinho DB, Almeida JF, Alves GM, Macedo LM, Porto JE, Vêncio EF, Colugnati DB, Santos RA, Ferreira AJ, Mendes EP, Castro CH. Angiotensin II type 1 receptor blockade restores angiotensin-(1-7)-induced coronary vasodilation in hypertrophic rat hearts. Clin Sci (Lond). 2013;125:449-459. doi: 10.1042/CS20120519.
5. Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension. 1998;31 (1 pt 2):356-361. doi: 10.1161/01. HYP.31.1.356.
6. De Mello WC, Ferrario CM, Jessup JA. Beneficial versus harmful effects of Angiotensin (1-7) on impulse propagation and cardiac arrhythmias in the failing heart. J Renin Angiotensin Aldosterone Syst. 2007;8:74-80. doi: 10.3317/jraas.2007.015.
7. Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol. 2006;290:H2417-H2423. doi: 10.1152/ ajpheart.01170.2005.
8. Trask AJ, Ferrario CM. Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev. 2007;25:162-174. doi: 10.1111/j.1527-3466.2007.00012.x.
9. Ferreira AJ, Santos RA. Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res. 2005;38:499-507. doi: /S0100-879X2005000400003.
10. Raizada MK, Ferreira AJ. ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol. 2007;50:112-119. doi: 10.1097/ FJC.0b013e3180986219.
11. Santos RA, Ferreira AJ, Pinheiro SV, Sampaio WO, Touyz R, Campagnole-Santos MJ. Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin Investig Drugs. 2005;14:1019-1031. doi: 10.1517/13543784.14.8.1019.
12. Marcus Y, Shefer G, Sasson K, Kohen F, Limor R, Pappo O, Nevo N, Biton I, Bach M, Berkutzki T, Fridkin M, Benayahu D, Shechter Y, Stern N. Angiotensin 1-7 as means to prevent the metabolic syndrome: lessons from the fructose-fed rat model. Diabetes. 2013;62:1121-1130. doi: 10.2337/db12-0792.
13. Oh YB, Kim JH, Park BM, Park BH, Kim SH. Captopril intake decreases body weight gain via angiotensin-(1-7). Peptides. 2012;37:79-85. doi: 10.1016/j.peptides.2012.06.005.
14. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med. 1981;304:930-933. doi: 10.1056/NEJM198104163041602.
15. Marcus Y, Shefer G, Stern N. Adipose tissue renin-angiotensin-aldosterone system (RAAS) and progression of insulin resistance. Mol Cell Endocrinol. 2013;378:1-14. doi: 10.1016/j.mce.2012.06.021.
16. Nadler JL, Natarajan R, Stern N. Specific action of the lipoxygenase pathway in mediating angiotensin II-induced aldosterone synthesis in isolated adrenal glomerulosa cells. J Clin Invest. 1987;80:1763-1769. doi: 10.1172/JCI113269.
17. Stern N, Yanagawa N, Saito F, Hori M, Natarajan R, Nadler J, Tuck M. Potential role of 12 hydroxyeicosatetraenoic acid in angiotensin II-induced calcium signal in rat glomerulosa cells. Endocrinology. 1993;133:843-847. doi: 10.1210/endo.133.2.8344221.
18. Benter IF, Yousif MH, Cojocel C, Al-Maghrebi M, Diz DI. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol. 2007;292:H666-H672. doi: 10.1152/ ajpheart.00372.2006.
19. Rebuffat P, Mazzocchi G, Gottardo G, Nussdorfer GG. Further studies on the involvement of dopamine and somatostatin in the inhibitory control of the growth and steroidogenic capacity of rat adrenal zona glomerulosa. Exp Clin Endocrinol. 1989;93:73-81. doi: 10.1055/s-0029-1210839.
20. Chartier L, Schiffrin EL. Role of calcium in effects of atrial natriuretic peptide on aldosterone production in adrenal glomerulosa cells. Am J Physiol. 1987;252 (4 pt 1):E485-E491.
21. Carbajal L, Biswas A, Niswander LM, Prizant H, Hammes SR. GPCR/ EGFR cross talk is conserved in gonadal and adrenal steroidogenesis but is uniquely regulated by matrix metalloproteinases 2 and 9 in the ovary. Mol Endocrinol. 2011;25:1055-1065. doi: 10.1210/me.2010-0410.
22. Eguchi S, Inagami T. Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase. Regul Pept. 2000;91:13-20.
23. Shah BH, Baukal AJ, Shah FB, Catt KJ. Mechanisms of extracellularly regulated kinases. activation in adrenal glomerulosa cells by lysophosphatidic acid and epidermal growth factor. Mol Endocrinol. 2005;19:2535-2548. doi: 10.1210/me.2005-0082.
24. Akhtar S, Chandrasekhar B, Attur S, Dhaunsi GS, Yousif MH, Benter IF. Transactivation of ErbB Family of Receptor Tyrosine Kinases Is Inhibited by Angiotensin-(1-7) via Its Mas Receptor. PLoS One. 2015;10:e0141657. doi: 10.1371/journal.pone.0141657.
25. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33-41. doi: 10.1056/NEJMoa033263.
26. Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol. 2013;9:459-469. doi: 10.1038/ nrneph.2013.110.
27. DeMarco VG, Habibi J, Jia G, Aroor AR, Ramirez-Perez FI, Martinez-Lemus LA, Bender SB, Garro M, Hayden MR, Sun Z, Meininger GA, Manrique C, Whaley-Connell A, Sowers JR. Low-dose mineralocorticoid receptor blockade prevents western diet-induced arterial stiffening in female mice. Hypertension. 2015;66:99-107. doi: 10.1161/ HYPERTENSIONAHA.115.05674.
28. Kumagai E, Adachi H, Jacobs DR Jr, et al. Plasma aldosterone levels and development of insulin resistance: prospective study in a general population. Hypertension. 2011;58:1043-1048. doi: 10.1161/ HYPERTENSIONAHA.111.180521.
29. Beygui F, Montalescot G, Vicaut E, Rouanet S, Van Belle E, Baulac C, Degrandsart A, Dallongeville J; OPERA Investigators. Aldosterone and long-term outcome after myocardial infarction: A substudy of the french nationwide Observatoire sur la Prise en charge hospitalière, l'Evolution à un an et les caRactéristiques de patients présentant un infArctus du myocarde avec ou sans onde Q (OPERA) study. Am Heart J. 2009;157:680-687. doi: 10.1016/j.ahj.2008.12.013.